<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="850">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01917344</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-P00003864</org_study_id>
    <nct_id>NCT01917344</nct_id>
  </id_info>
  <brief_title>The Brain, Neurological Features and Neuropsychological Functioning in Adults With Phenylketonuria: A Pilot Study</brief_title>
  <official_title>The Brain, Neurological Features and Neuropsychological Functioning in Adults With Phenylketonuria: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Boston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Boston</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Newborn screening and early treatment prevent the most severe manifestations of
      phenylketonuria (PKU). However, executive functioning deficits, attention deficit disorder,
      slow processing speed, and visual-motor problems commonly occur. Many adults with this
      disorder also suffer depression and anxiety. Using advanced electroencephalogram (EEG) and
      magnetic resonance imaging (MRI) techniques, including novel MR spectroscopy (MRS) we hope
      to discover why this distinct constellation of deficits occurs in PKU. Adult subjects with
      PKU will undergo EEG and comprehensive MRI evaluations, including a novel method of MR
      spectroscopy to determine brain phenylalanine levels. In addition, they will receive
      neurological and neuropsychological examinations and dietary evaluation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Phenylalanine Level in the Brain as Determined by MR Spectroscopy and in Blood</measure>
    <time_frame>During period of evaluation, approximately 8 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Brain Phe levels (umol/L) using MRI correlated spectroscopy and Blood Phe levels (umol/L) obtained on the same day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Full Scale Intelligence Quotient (IQ)</measure>
    <time_frame>During period of evaluation, approximately 8 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electroencephalogram (EEG) Findings</measure>
    <time_frame>During period of evaluation, approximately 8 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volumetric MRI Findings</measure>
    <time_frame>During period of evaluation, approximately 8 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diffusion Tensor Imaging (DTI) Findings Through MRI</measure>
    <time_frame>During period of evaluation, approximately 8 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tremor as Determined Through Neurological Evaluation</measure>
    <time_frame>During period of evaluation, approximately 8 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Phenylketonuria</condition>
  <arm_group>
    <arm_group_label>Adults with PKU</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MRI, EEG, neuropsychological testing, neurological examination, blood draw, diet diary, physical examination. These activities were performed for the study, but no drug or other interventions took place.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <arm_group_label>Adults with PKU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult with classic PKU who has been seen at one of the hospitals collaborating in
             this study

          2. Age 18-55 years

          3. Medical Records available that include genotype and blood phenylalanine levels during
             the first 6 years of life. (We have over 300 patients with PKU with genotypes in our
             clinic, of whom about half are adults.)

          4. Capable of providing informed consent

          5. Able to undergo MRI procedures without sedating medication

          6. Does not have metal implants

          7. Not currently on Kuvan, Large Neutral Amino Acid therapy or involved in any clinical
             trials.

        Exclusion Criteria:

          1. Mild PKU or mild hyperphenylalaninemia

          2. Less than 18 years old or great than 55 years old

          3. No medical records available for the first 6 years of life

          4. No record of genotype

          5. Not capable of providing informed consent

          6. Not able to undergo MRI without sedating medication

          7. Has metal implants

          8. Currently taking Kuvan, Large Neutral Amino Acid therapy or involved in any clinical
             trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan E Waisbren, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Boston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 2, 2015</lastchanged_date>
  <firstreceived_date>August 5, 2013</firstreceived_date>
  <firstreceived_results_date>May 8, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Boston</investigator_affiliation>
    <investigator_full_name>Susan Waisbren</investigator_full_name>
    <investigator_title>Susan Waisbren, P.h.D</investigator_title>
  </responsible_party>
  <keyword>Phenylketonuria</keyword>
  <keyword>MRI</keyword>
  <keyword>Neuropsychological functioning</keyword>
  <keyword>Neurological functioning</keyword>
  <keyword>EEG</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Phenylketonurias</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A recruitment letter was sent to adults with PKU who were not enrolled in another clinical trial.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Adults With PKU</title>
          <description>MRI, EEG, neuropsychological testing, neurological examination, blood draw, diet diary, physical examination
MRI</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Adults (ages 18 and older) with phenylketonuria (PKU)</population>
      <group_list>
        <group group_id="B1">
          <title>Adults With PKU</title>
          <description>MRI, EEG, neuropsychological testing, neurological examination, blood draw, diet diary, physical examination
MRI</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Brain and Blood Phenylalanine</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29" spread="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phenylalanine Level in the Brain as Determined by MR Spectroscopy and in Blood</title>
        <description>Brain Phe levels (umol/L) using MRI correlated spectroscopy and Blood Phe levels (umol/L) obtained on the same day.</description>
        <time_frame>During period of evaluation, approximately 8 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Adults With PKU</title>
            <description>MRI, EEG, neuropsychological testing, neurological examination, blood draw, diet diary, physical examination
MRI</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Phenylalanine Level in the Brain as Determined by MR Spectroscopy and in Blood</title>
            <description>Brain Phe levels (umol/L) using MRI correlated spectroscopy and Blood Phe levels (umol/L) obtained on the same day.</description>
            <units>umol/L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>White Matter</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="130" spread="38"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gray Matter</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="137" spread="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood Phe level</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="961" spread="378"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Full Scale Intelligence Quotient (IQ)</title>
        <time_frame>During period of evaluation, approximately 8 hours</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Electroencephalogram (EEG) Findings</title>
        <time_frame>During period of evaluation, approximately 8 hours</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volumetric MRI Findings</title>
        <time_frame>During period of evaluation, approximately 8 hours</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diffusion Tensor Imaging (DTI) Findings Through MRI</title>
        <time_frame>During period of evaluation, approximately 8 hours</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tremor as Determined Through Neurological Evaluation</title>
        <time_frame>During period of evaluation, approximately 8 hours</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Two years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adults With PKU</title>
          <description>MRI, EEG, neuropsychological testing, neurological examination, blood draw, diet diary, physical examination
MRI</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susan Waisbren, P.h.D</name_or_title>
      <organization>Boston Children's Hospital</organization>
      <phone>617-355-7346</phone>
      <email>susan.waisbren@childrens.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
